Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aytu Biopharma Inc
(NQ:
AYTU
)
2.893
UNCHANGED
Streaming Delayed Price
Updated: 3:35 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aytu Biopharma Inc
< Previous
1
2
3
Next >
Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients
January 10, 2023
Via
ACCESSWIRE
Aytu BioPharma Announces 1-for-20 Reverse Stock Split
January 05, 2023
Via
ACCESSWIRE
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect
November 30, 2022
Via
ACCESSWIRE
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
November 22, 2022
Via
ACCESSWIRE
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row
November 17, 2022
Via
ACCESSWIRE
Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023
November 14, 2022
Via
ACCESSWIRE
Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan
October 25, 2022
Via
ACCESSWIRE
Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply Disruptions
October 05, 2022
Via
ACCESSWIRE
Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue
September 27, 2022
Via
ACCESSWIRE
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso
November 16, 2022
Via
ACCESSWIRE
Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022
November 07, 2022
Via
ACCESSWIRE
Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs
October 13, 2022
Via
ACCESSWIRE
Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022
September 20, 2022
Via
ACCESSWIRE
Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin
September 14, 2022
Via
ACCESSWIRE
Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
August 16, 2022
Via
ACCESSWIRE
Aytu BioPharma to Participate in September 2022 Investor Conferences
August 24, 2022
Via
ACCESSWIRE
Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering
August 15, 2022
Via
ACCESSWIRE
Aytu BioPharma Announces Pricing of Public Offering
August 09, 2022
Via
ACCESSWIRE
Aytu BioPharma Announces Launch of Public Offering
August 08, 2022
Via
ACCESSWIRE
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
July 26, 2022
Via
ACCESSWIRE
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
July 26, 2022
ENGLEWOOD, CO / ACCESSWIRE / July 26, 2022 / Aytu BioPharma, Inc. (the "Company") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
July 20, 2022
Via
ACCESSWIRE
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
July 20, 2022
ENGLEWOOD, CO / ACCESSWIRE / July 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the initiation of...
From
Aytu BioPharma, Inc.
Via
AccessWire
Exposures
Product Safety
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors
June 29, 2022
ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference
June 13, 2022
ENGLEWOOD, CO / ACCESSWIRE / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities
May 16, 2022
Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company History Strategic Priorities Focused on Driving Revenue Growth, Increasing Financial Efficiencies and...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology
April 25, 2022
Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Delaying Time to Development of Ventilator-Associated Pneumonia ENGLEWOOD, CO / ACCESSWIRE / April 25, 2022 / Aytu...
From
Aytu BioPharma, Inc.
Via
AccessWire
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome
April 19, 2022
ENGLEWOOD, CO / ACCESSWIRE / April 19, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the U.S....
From
Aytu BioPharma, Inc.
Via
AccessWire
Exposures
Product Safety
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)
March 23, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 23, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that its newly...
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
March 22, 2022
ENGLEWOOD, CO / ACCESSWIRE / March 22, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that management...
From
Aytu BioPharma, Inc.
Via
AccessWire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.